 |
1 Disease |  |
15 Trials |
|
15 Trials |  |
102 News |  |
| 12» |
- ||| afimkibart (RG6631) / Roche
Trial completion date: SIBERITE-2: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Nov 12, 2025
P3, N=425, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2028 --> Apr 2029
- |||| afimkibart (RG6631) / Roche
New P2 trial: Velarite-LTE: A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis (clinicaltrials.gov) - Nov 3, 2025
P2, N=120, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | afimkibart (RG6631) / Roche
New P3 trial: A Phase III, multicenter, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of induction therapy with RO7790121 in patients suffering from moderately to severely active ulcerative colitis. (EUDRACT) - Oct 30, 2025
P3, N=350, Recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- || afimkibart (RG6631) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis (clinicaltrials.gov) - Oct 16, 2025
P1, N=50, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2028 --> Apr 2029 Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
- afimkibart (RG6631) / Roche
Rationale and Design of the FIBROLITE Study Evaluating Safety, Pharmacokinetics, and Pharmacodynamics of Afimkibart in Patients with Advanced Liver Fibrosis (Convention Center: Hall DE 1443-1480 Posters) - Oct 7, 2025 - Abstract #AASLD2025AASLD_1509;
P1
Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026 While resmetirom is approved for the treatment of MASH with moderate to advanced fibrosis (F2
- LBL-053, A Novel Anti-TL1A/p40 Bispecific Antibody for the Treatment of Autoimmune Disorders. [WITHDRAWN] (Hall F1) - Sep 15, 2025 - Abstract #ACRConvergence2025ACR_Convergence_1524;
Ustekinumab, targeting p40 subunit, has demonstrated robust efficacy and approved for IBD...The effect of LBL-053 on inhibiting TL1A-DR3 downstream signaling pathway was comparabile to RVT-3101, but better than MK-7240 and PF-07261271.LBL-053 also significantly blocked IL-23/IL-12R?1 interaction... LBL-053 showed dual immunosuppressive functions, simultaneously inhibiting TL1A-DR3 and IL-23/IL-12R?1 signaling pathway, indicating promising clinical applications for the treatment of autoimmune diseases.
- |||||||| afimkibart (RG6631) / Roche
New P3 trial: AMETRINE-PEDS: A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Sep 5, 2025
P3, N=100, Not yet recruiting, Sponsor: Hoffmann-La Roche
- afimkibart (RG6631) / Roche
Baseline Characteristics Associated With Probability of Remission and Greater Absolute Benefit of Treatment With Afimkibart (RO7790121/RG6631) (Exhibit Hall) - Aug 29, 2025 - Abstract #ACG2025ACG_1681;
P2
LBL-053 showed dual immunosuppressive functions, simultaneously inhibiting TL1A-DR3 and IL-23/IL-12R?1 signaling pathway, indicating promising clinical applications for the treatment of autoimmune diseases. Overall, 32.5% of pts achieved clinical remission by mMS at W14 in the afimkibart arm (65/200; 90% CI 27.3
- |||| afimkibart (RG6631) / Roche
New P2 trial: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) (clinicaltrials.gov) - Aug 23, 2025
P2, N=160, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || afimkibart (RG6631) / Roche
Trial primary completion date: A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Jul 25, 2025
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Overall, 32.5% of pts achieved clinical remission by mMS at W14 in the afimkibart arm (65/200; 90% CI 27.3 Trial primary completion date: May 2026 --> Aug 2026
- afimkibart (RG6631) / Roche
AFIMKIBART (ANTI-TL1A) IS EFFECTIVE IN THE BLOCKADE OF CELLULAR SIGNALING INDUCED BY ACTIVE TL1A (Science Lounge) - Jul 9, 2025 - Abstract #UEGW2025UEGW_2856;
While some signaling activity was observed at high concentrations of monomeric TL1A protein, we hypothesize that any signaling observed with monomeric form is likely due to the formation of trimers, which are efficiently blocked by afimkibart. Overall, any monomeric TL1A present should not be functionally active nor be available as a sink for afimkibart, thus preserving the optimal pharmacokinetic (PK) and pharmacodynamic (PD) properties needed for effective target inhibition.
- afimkibart (RG6631) / Roche
BASELINE CHARACTERISTICS ASSOCIATED WITH PROBABILITY OF REMISSION AND GREATER ABSOLUTE BENEFIT OF TREATMENT WITH AFIMKIBART (RO7790121/RG6631) (Poster Stage 6) - Jul 8, 2025 - Abstract #UEGW2025UEGW_1733;
P2
This analysis demonstrates how precision medicine approaches, that account for diverse characteristics, may improve interpretation of positive IBD clinical trial results. Integrating genetic and novel biomarkers alongside clinical features could help to better predict individual outcomes for pts with IBD.
- SIM0709 / Simcere
DEVELOPMENT AND CHARACTERIZATION OF SIM0709, A NOVEL HALF-LIFE EXTENDED BI-SPECIFIC ANTIBODY SIMULTANEOUSLY TARGETING TL1A AND IL-23P19 FOR THE TREATMENT OF IBD AND BEYOND (Poster Stage 4) - Jul 8, 2025 - Abstract #UEGW2025UEGW_597;
SIM0709 simultaneously bound to both TL1A and IL-23 proteins with sub-nanomolar affinity and demonstrated superior functional activities under various functional assays on both TL1A and IL-23 axes compared to that of benchmark anti-TL1A mAb RG6631 and Guselkumab or its combination, respectively. Taken together, these data support the further development of SIM0709 as a potential FIC and BIC therapeutic agent for the treatment of IBD with expected first-in-human study in H1 2026.
- FIRST-IN-CLASS ORAL TL1A NANOBODY AND LONG-ACTING TL1A/IL-23 BISPECIFIC NANOBODY: NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE () - Apr 17, 2025 - Abstract #DDW2025DDW_8739;
- |||||| afimkibart (RG6631) / Roche
Enrollment open: SIBERITE-2: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Apr 7, 2025
P3, N=425, Recruiting, Sponsor: Hoffmann-La Roche
Taken together, these data support the further development of SIM0709 as a potential FIC and BIC therapeutic agent for the treatment of IBD with expected first-in-human study in H1 2026. Not yet recruiting --> Recruiting
- | afimkibart (RG6631) / Roche
New P3 trial: RO7790121 as an induction therapy efficacy and safety study in subjects with moderately to severely active Crohn's disease (EUDRACT) - Apr 2, 2025
P3, N=425, Not yet recruiting, Sponsor: Peking Union Medical College Hospital Chinese Academy of Medical Sciences; Peking Union Medical College Hospital Chinese Academy of Medical Sciences
- | afimkibart (RG6631) / Roche
New P3 trial: A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study To Assess The Efficacy And Safety Of Induction And Maintenance Therapy With RO7790121 In Patients With Moderately To Severely Active Crohn's Disease (EUDRACT) - Apr 2, 2025
P3, N=600, Not yet recruiting, Sponsor: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- ||| afimkibart (RG6631) / Roche
Enrollment open: A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Apr 1, 2025
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || afimkibart (RG6631) / Roche
New P1 trial: A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis (clinicaltrials.gov) - Mar 30, 2025
P1, N=50, Recruiting, Sponsor: Hoffmann-La Roche
- |||||| afimkibart (RG6631) / Roche
Enrollment open: SIBERITE-1: A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Mar 10, 2025
P3, N=600, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| afimkibart (RG6631) / Roche
Trial completion date: SIBERITE-2: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Mar 9, 2025
P3, N=425, Not yet recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial completion date: Dec 2033 --> Dec 2028
- afimkibart (RG6631) / Roche
TREATMENT WITH RO7790121 INDUCES AND MAINTAINS HISTOLOGIC AND HISTOLOGIC-ENDOSCOPIC IMPROVEMENT AND REMISSION IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (20D - SDCC) - Mar 8, 2025 - Abstract #DDW2025DDW_6411;
P2, P3
Similarly, a higher proportion of pts treated with RO7790121 achieved histologic-endoscopic mucosal improvement and remission, sustained through Week 56. RO7790121 is currently being investigated in phase III studies (NCT06589986 and NCT06588855).
- afimkibart (RG6631) / Roche
RO7790121 SHOWS EARLY AND RAPID SYMPTOMATIC REMISSION IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (Halls C-E, Lower Level - SDCC) - Mar 8, 2025 - Abstract #DDW2025DDW_3799;
P3
These results indicate early symptom relief and a favorable safety profile for pts treated with RO7790121, supporting its further clinical development. RO7790121 is currently being evaluated in phase III studies (NCT06589986 and NCT06588855).
- HXN-1003 / Sanofi, RG6631 / Roche, Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
DESIGN AND DEVELOPMENT OF A BISPECIFIC ANTIBODY TARGETING IL23 AND TL1A FOR ENHANCED THERAPEUTIC EFFICACY (Halls C-E, Lower Level - SDCC) - Mar 8, 2025 - Abstract #DDW2025DDW_2995;
The anti-TL1A arm of HXN-1003 binds both the trimeric and monomeric forms of TL1A with sub-nanomolar affinity, exhibiting strong blocking activity in TF-1 apoptosis assays and DR3-NF?B-Luc reporter assays, with results comparable to its parent antibody HXN-1001 and the benchmark RVT-3101...The TL1A/IL23 bsAb targets two key drivers of immune dysregulation in autoimmune diseases, demonstrating both synergistic and additive therapeutic effects in vitro and in vivo. These results highlight its potential to improve clinical outcomes in patients with autoimmune diseases across multiple indications.
- AI-GUIDED DESIGN AND DEVELOPMENT OF HXN-1001: A POTENT, HALF-LIFE-EXTENDED ANTI-TL1A ANTIBODY (Halls C-E, Lower Level - SDCC) - Mar 8, 2025 - Abstract #DDW2025DDW_2986;
In addition, in an imiquimod (IMQ)-induced psoriasis model, HXN-1001 outperformed the marketed anti-IL23 monoclonal antibody Risankizumab in reducing psoriatic-like inflammation, suggesting its utility in broader immune-mediated conditions...The preclinical data collectively establish HXN-1001 as a promising therapeutic candidate with broad immunomodulatory capabilities, superior efficacy compared to current standards, and an extended dosing profile suited for chronic inflammatory and autoimmune diseases. HXN-1001 is anticipated to enter clinical development in Q2 2025.
- |||| afimkibart (RG6631) / Roche
New P2 trial: A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Mar 7, 2025
P2, N=160, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||||||||| afimkibart (RG6631) / Roche
New P3 trial: SIBERITE-1: A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Feb 11, 2025
P3, N=600, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||||||||| afimkibart (RG6631) / Roche
New P3 trial: SIBERITE-2: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Feb 11, 2025
P3, N=425, Not yet recruiting, Sponsor: Hoffmann-La Roche
- RG6631 / Roche
Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active ulcerative colitis (Plenary Hall / Hall B) - Dec 21, 2024 - Abstract #ECCOIBD2025ECCO_IBD_1312;
P2, P3
Similarly, a higher proportion of pts treated with RO7790121 achieved histologic-endoscopic mucosal improvement and remission, sustained through Week 56. RO7790121 is currently being investigated in phase III studies (NCT06589986 and NCT06588855).
- Development and characterization of LQ080, a novel extended half-life bispecific TL1A/IL-23 p19 single domain antibody for the treatment of IBD (Poster exhibition) - Dec 21, 2024 - Abstract #ECCOIBD2025ECCO_IBD_990;
No large immune complex formation when mixed with TL1A and IL-23 would make LQ080 safer when administrated by SC route. Overall, LQ080 is a promising TL1A/IL-23 p19 sdAb for IBD treatment.
- RG6631 / Roche
RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active ulcerative colitis (A8) - Dec 21, 2024 - Abstract #ECCOIBD2025ECCO_IBD_562;
P3
These results indicate early symptom relief and a favorable safety profile for pts treated with RO7790121, supporting its further clinical development. RO7790121 is currently being evaluated in phase III studies (NCT06589986 and NCT06588855).
- SL-325 / Shattuck
Pre-Clinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the DR3/TL1A Axis in Inflammatory Bowel Disease (A5) - Dec 21, 2024 - Abstract #ECCOIBD2025ECCO_IBD_409;
No evidence of residual DR3 agonist activity was observed. Conclusion These results indicate SL-325 is a high-affinity DR3 blocking antibody with no evidence of toxicity or residual agonism in cynomolgus macaques, and with an RO/PK profile suggestive of extended dosing intervals that will be studied in an upcoming Phase 1 clinical trial.
- || RG6631 / Roche, tulisokibart (MK-7240) / Merck (MSD)
Review, Journal: Antibodies targeting the tumor necrosis factor (TNF) -like ligand 1A (TL1A) in Inflammatory Bowel Disease - a new kid on the (biologics) block? (Pubmed Central) - Dec 9, 2024
With regard to the available data the risk/benefit profile of TL1A inhibitors seems to be promising. This article gives a short update and overview, where we are at this point in time with antibodies targeting the TL1A protein in IBD.
- | afimkibart (RG6631) / Roche
Trial completion date, Trial primary completion date: TAHOE: RO7790121 for the Treatment of Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) - Sep 27, 2024
P2, N=21, Active, not recruiting, Sponsor: Hoffmann-La Roche
This article gives a short update and overview, where we are at this point in time with antibodies targeting the TL1A protein in IBD. Trial completion date: Dec 2025 --> Dec 2030 | Trial primary completion date: Jul 2024 --> Dec 2030
- |||||||||| afimkibart (RG6631) / Roche
New P3 trial: Ametrine-2: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Sep 20, 2024
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
- |||||||||| afimkibart (RG6631) / Roche
New P3 trial: Ametrine-1: A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Sep 19, 2024
P3, N=400, Recruiting, Sponsor: Hoffmann-La Roche
- RG6631 / Roche
TUSCANY-2: A Dose-Ranging Phase IIb Study Evaluating Efficacy and Safety of RO7790121, an Antibody Against Tumor Necrosis Factor-Like Ligand 1A (Anti-TL1A) in Adults With Moderately to Severely Active Ulcerative Colitis (Terrace Ballroom 2-3) - Aug 20, 2024 - Abstract #ACG2024ACG_499;
P2
At week 14, a greater proportion of patients across all treatment doses achieved remission vs PBO by both tMS (p >0.05) and mMS (nominal p < 0.05), sustained through week 56 (Table). Patients receiving any dose of RO7790121 showed greater endoscopic improvement vs PBO at weeks 14 and 56 (Table).
- RG6631 / Roche, duvakitug (SAR447189) / Sanofi, tulisokibart (MK-7240) / Merck (MSD)
DISCOVERY AND CHARACTERIZATION OF A NOVEL HIGH-AFFINITY ANTI-TL1A MONOCLONAL ANTIBODY WITH EXTENDED HALF-LIFE FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (Poster Stage 1) - Jul 18, 2024 - Abstract #UEGW2024UEGW_3021;
In human FcRn knock-in mice and in cynomolgus monkeys, these antibodies show an extended half-life consistent with FDA-approved antibodies using the XtendTM technology. These data demonstrate the therapeutic potential of the clinical candidate antibodies in the treatment of TL1A-mediated diseases such as ulcerative colitis and Crohn
- CHARACTERIZATION OF TWO NOVEL EXTENDED HALF-LIFE MONOCLONAL ANTIBODY DRUG CANDIDATES TARGETING TL1A FOR THE TREATMENT OF IBD (Poster Stage 1) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2709;
With an extended half-life observed in NHP, both SPY002-091 and SPY002-072 demonstrate therapeutic potential for effective and safe treatment of CD and UC with the advantage of infrequent SC dosing. Further preclinical and clinical studies are warranted to demonstrate this potential.
- RG6631 / Roche
EFFICACY AND SAFETY OF RO7790121, A FULLY HUMAN MONOCLONAL ANTIBODY BLOCKING TUMOUR NECROSIS FACTOR-LIKE LIGAND 1A IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING PHASE 2B TUSCANY-2 STUDY (Lehar 3) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2251;
P2
A phase 3 study will be conducted to confirm these results.Table. Summary of efficacy outcomes at week 14 and week 56Induction, week 14PBO(n=43)50mg (n=47)150mg (n=60)450mg(n=88)Clinical remission by tMS,* % (90% CI) 11.6 (5.8
- || RG6631 / Roche, SAR447189 / Teva, Sanofi, tulisokibart (MK-7240) / Merck (MSD)
Review, Journal: TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis. (Pubmed Central) - May 11, 2024
Results are eagerly awaited, marking advancements in IBD therapeutics. This critical review comprehensively examines the existing literature, illuminating TL1A and the intricate role of DR3 in IBD, emphasizing the evolving therapeutic landscape and ongoing clinical trials, with potential implications for more effective IBD management.
- || afimkibart (RG6631) / Roche
New P2 trial: RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) - Apr 16, 2024
P2, N=20, Active, not recruiting, Sponsor: Hoffmann-La Roche
- ||| afimkibart (RG6631) / Roche
Enrollment closed, Enrollment change, Trial primary completion date: TAHOE: RO7790121 for the Treatment of Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) - Feb 2, 2024
P2, N=20, Active, not recruiting, Sponsor: Hoffmann-La Roche
This critical review comprehensively examines the existing literature, illuminating TL1A and the intricate role of DR3 in IBD, emphasizing the evolving therapeutic landscape and ongoing clinical trials, with potential implications for more effective IBD management. Recruiting --> Active, not recruiting | N=105 --> 20 | Trial primary completion date: Dec 2024 --> Jul 2024
- | afimkibart (RG6631) / Roche
Phase classification: A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Jan 19, 2024
P2, N=246, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=105 --> 20 | Trial primary completion date: Dec 2024 --> Jul 2024 Phase classification: P2b --> P2
- SPY002 / Aeglea
Development and Characterization of SPY002, a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting TL1A for the Treatment of IBD (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_777;
With an extended half-life in NHP, SPY002 demonstrates therapeutic potential for effective and safe treatment of CD and UC with the advantage of infrequent SC dosing. Further preclinical and clinical studies are warranted to demonstrate this potential.
- ||| afimkibart (RG6631) / Roche
Enrollment open: TAHOE: RO7790121 for the Treatment of Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) - Jul 3, 2023
P2, N=105, Recruiting, Sponsor: Telavant, Inc.
Further preclinical and clinical studies are warranted to demonstrate this potential. Not yet recruiting --> Recruiting
- | afimkibart (RG6631) / Roche
New P2 trial: TAHOE: RO7790121 for the Treatment of Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) - Jun 18, 2023
P2, N=105, Not yet recruiting, Sponsor: Telavant, Inc.
- | afimkibart (RG6631) / Roche
Enrollment change, Trial withdrawal: Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Mar 23, 2023
P2a, N=0, Withdrawn, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=164 --> 0 | Not yet recruiting --> Withdrawn
- |||| afimkibart (RG6631) / Roche
Trial completion: A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Nov 22, 2022
P2b, N=246, Completed, Sponsor: Pfizer
N=164 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- | PF-06480605 / Pfizer, PRA023 / Prometheus
$RXDX banging the table re differentiation of PRA023 vs $PFE PF-06480605. Better target engagement, higher bioavailability etc #Jefferies22 (Twitter) - Nov 17, 2022